Nanotherapeutics, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Nanotherapeutics, Inc. – Product Pipeline Review – 2016’, provides an overview of the Nanotherapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Nanotherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Nanotherapeutics, Inc.

The report provides overview of Nanotherapeutics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Nanotherapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Nanotherapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Nanotherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Nanotherapeutics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nanotherapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Nanotherapeutics, Inc. Snapshot 6

Nanotherapeutics, Inc. Overview 6

Key Information 6

Key Facts 6

Nanotherapeutics, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Nanotherapeutics, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Nanotherapeutics, Inc. - Pipeline Products Glance 15

Nanotherapeutics, Inc. - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

Nanotherapeutics, Inc. - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Nanotherapeutics, Inc. - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Nanotherapeutics, Inc. - Drug Profiles 20

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ross river virus vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

(buprenorphine hydrochloride + naloxone hydrochloride) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

influenza [strain A/H9N2] vaccine 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

NTC-942 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

NTO-1151 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ramoplanin 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

influenza [strain A/H5N1] vaccine 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

West Nile virus vaccine 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

XOMA-3AB 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

chikungunya vaccine 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

influenza [strain A/H7N9] vaccine 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

middle east respiratory syndrome vaccine + severe acute respiratory syndrome vaccine 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

norovirus (bivalent) virus like particle vaccine 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Rotavirus vaccine 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

typhoid vaccine 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Nanotherapeutics, Inc. - Pipeline Analysis 39

Nanotherapeutics, Inc. - Pipeline Products by Target 39

Nanotherapeutics, Inc. - Pipeline Products by Route of Administration 40

Nanotherapeutics, Inc. - Pipeline Products by Molecule Type 41

Nanotherapeutics, Inc. - Pipeline Products by Mechanism of Action 42

Nanotherapeutics, Inc. - Recent Pipeline Updates 43

Nanotherapeutics, Inc. - Dormant Projects 46

Nanotherapeutics, Inc. - Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Nanotherapeutics, Inc., Key Information 6

Nanotherapeutics, Inc., Key Facts 6

Nanotherapeutics, Inc. – Pipeline by Indication, 2016 8

Nanotherapeutics, Inc. – Pipeline by Stage of Development, 2016 10

Nanotherapeutics, Inc. – Monotherapy Products in Pipeline, 2016 11

Nanotherapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2016 12

Nanotherapeutics, Inc. – Partnered Products in Pipeline, 2016 13

Nanotherapeutics, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 14

Nanotherapeutics, Inc. – Pre-Registration, 2016 15

Nanotherapeutics, Inc. – Phase III, 2016 16

Nanotherapeutics, Inc. – Phase II, 2016 17

Nanotherapeutics, Inc. – Phase I, 2016 18

Nanotherapeutics, Inc. – Preclinical, 2016 19

Nanotherapeutics, Inc. – Pipeline by Target, 2016 39

Nanotherapeutics, Inc. – Pipeline by Route of Administration, 2016 40

Nanotherapeutics, Inc. – Pipeline by Molecule Type, 2016 41

Nanotherapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 42

Nanotherapeutics, Inc. – Recent Pipeline Updates, 2016 43

Nanotherapeutics, Inc. – Dormant Developmental Projects,2016 46

Nanotherapeutics, Inc., Other Locations 47

List of Figures

List of Figures

Nanotherapeutics, Inc. – Pipeline by Top 10 Indication, 2016 8

Nanotherapeutics, Inc. – Pipeline by Stage of Development, 2016 10

Nanotherapeutics, Inc. – Monotherapy Products in Pipeline, 2016 11

Nanotherapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2016 12

Nanotherapeutics, Inc. – Pipeline by Target, 2016 39

Nanotherapeutics, Inc. – Pipeline by Route of Administration, 2016 40

Nanotherapeutics, Inc. – Pipeline by Molecule Type, 2016 41

Nanotherapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 42

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports